FDA Approves Roche ’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Roche announced today that the US Food and Drug Administration (FDA) has approved ENSPRYNG ™ (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news